CYFIP2 and breast cancer: High expression of CYFIP2 was identified as a favorable prognostic factor in LUAD (HR = 0.61, 95% CI 0.45–0.84, log-rank P < 0.01), thymoma (HR = 0.06, 95% CI 0.01–0.47, log-rank P < 0.01), sarcoma (HR = 0.54, 95% CI 0.36–0.82, log-rank P < 0.01), PDAC (HR = 0.43, 95% CI 0.28–0.67, log-rank P < 0.01), clear cell RCC (HR = 0.34, 95% CI 0.25–0.46, log-rank P < 0.01), BC (HR = 0.73, 95% CI 0.54–0.98, log-rank P = 0.035).